藥明巨諾-B(02126.HK)獲主要股東Juno授出實體瘤抗原新細胞治療產品大中華專利權
藥明巨諾-B(02126.HK)公佈,與主要股東Juno將建立戰略聯盟,在大中華研發、生產及商業化專門針對DLL3實體瘤抗原的新細胞治療產品。
根據許可及合作協議,Juno已授予公司由Juno控制的若幹專利及專有技術的權利和許可,該等權利和許可對於在大中華開發、生產及商業化該產品屬必要或合理有用,且公司支付開發裏程碑付款及補償總額不逾3,500萬美元,而支付授權費及補償的總額不逾該產品在大中華年度銷售淨額的16%。
Juno爲百時美施貴寶(BMY.US)旗下生物技術公司,專注開發治療癌症的創新細胞免疫療法。截至目前,Juno直接持有公司約17.09%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.